Pharmacokinetic Evaluation of MDZ028 After Single Administration of a New Oral Form, at the Time of Anesthetic Premedication in Children.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 37
- 主要终点
- Pharmacokinetic analysis of the oral solution of midazolam (ADV6209)
研究概览
简要总结
Plasma concentration data were collected from 37 paedriatic patients and 12 healthy adults recruited in a single dose, open-label phase II pharmacokinetic study and in a single dose, randomised, open-label two-peiod crossover bioavailability study, respectively. Data were analysed using non-linear mixed effect modeling.
详细描述
In the absence of a licensed formulation in many countries worldwide, ADV6209, an innovative 2mg/ml oral solution of midazolam containing cyclodextrin, has been developed for moderate sedation in paediatric patients. Population pharmacokinetics for ADV6209 is reported.
Plasma concentration data were collected from 37 paedriatic patients and 12 healthy adults recruited in a single dose, open-label phase II pharmacokinetic study and in a single dose, randomised, open-label two-peiod crossover bioavailability study, respectively. Data were analysed using non-linear mixed effect modeling. Plasma concentrations of midazolam were discribed by a two-compartement model. An additional one-compartement model was added for a α-hydroxymidazolam.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 6 Months 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Child (boy or girl) for whom surgery under general anesthesia is scheduled.
- •Child aged 6 months to 17 years old.
- •Child with a body mass index between the 3rd and 97th percentile.
- •Child with ASA (American Society of Anesthesiology) status of I or II. Young girl of childbearing age (ie after puberty) and sexually active to have a result negative to the pregnancy test.
- •Child whose parents / legal representative (s) agree to sign a consent form.
- •Child whose opinion / agreement was / tried to be collected.
- •Child and parents / legal representative (s) being ready and able to participate in the study, understanding and undertaking to respect the study procedures throughout the duration of the study.
- •Child enrolled in a social security scheme.
排除标准
- •Child with midazolam allergy, benzodiazepine hypersensitivity or hypersensitivity known to one of the excipients of the formulation of the study.
- •Child with respiratory disease (severe respiratory failure, acute respiratory depression).
- •Child with heart disease.
- •Child with gastrointestinal disorders that may affect absorption or gastroesophageal reflux.
- •Child with growth disorders or abnormal weight-of-weight.
- •Child taking Cytochrome P450 Interactions Within 60 Days of Inclusion in the study.
- •Child with kidney failure, liver failure, history of myasthenia gravis, or neurological disease.
- •Pregnant or lactating girl.
- •Child who has a known human immunodeficiency virus (HIV) infection, or active hepatitis B, or active hepatitis C.
- •A child who could present any condition that may prevent his participation in the study, according to the judgment of the investigator.
研究组 & 干预措施
6 - 23 months
8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
干预措施: Midazolam (Drug)
2-11 years
17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
干预措施: Midazolam (Drug)
12-17 years
12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
干预措施: Midazolam (Drug)
结局指标
主要结局
Pharmacokinetic analysis of the oral solution of midazolam (ADV6209)
时间窗: 1 day
The Aim of the study was to assess the pharmacokinetic analysis of an oral solution of midazolam (ADV6209) oral formulation in paedriatic patients from 6 months to 18 years ols in order to support dosing recommendations. All subjects received a single 0.3mg/kg midazolam dose of ADV6209, without exceeding a total dose of 10 mg.Population pharmacokinetic modelling was performed to characterise the concentration-time course of midazolam and its main active metabolite, and to evaluate the changes in clearance and volume of distibution in the different age groups.
次要结局
未报告次要终点